Skip to main content
. 2018 Sep 11;14:1691–1700. doi: 10.2147/TCRM.S173041

Table 4.

Comparison of the survival of patients with advanced pancreatic cancer received PD-1/PD-L1 inhibitor in different lines of treatment

Lines of treatment mOS (months) 95% CI
First-line 7.0 2.057–11.938
Second-line 5.1 0.402–9.783
Multiple-line 2.8 0.724–4.927
P-value 0.161

Abbreviations: CI, confidence interval; mOS, median overall survival.